(Q50912095)

English

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.

scientific article published in March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. (English)

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

2

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

1

object named as

Roy W Jones

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

author name string

Fraser Inglis

3

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

Andrew Barker

4

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

Ravinder Phul

5

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

language of work or name

0 references

publication date

1 March 2007

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

International Journal of Geriatric Psychiatry

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

22

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

3

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

258-262

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1752

7 January 2021

based on heuristic

inferred from DOI database lookup

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1752

7 January 2021

based on heuristic

inferred from DOI database lookup

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1752

7 January 2021

based on heuristic

inferred from DOI database lookup

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1752

7 January 2021

based on heuristic

inferred from DOI database lookup

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1752

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/GPS.1752

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

1 reference

Europe PubMed Central

25 March 2018

http://europepmc.org/abstract/MED/17243195

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50912095&oldid=1977384103"